This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Serrano, J. Articles by Jensen, R. T. Search for Related Content PubMed PubMed Citation Articles by Serrano, J. Articles by Jensen, R. T. Pubmed/NCBI databases OMIM Substance via MeSH Medline Plus Health Information Intestinal Cancer Pancreatic Cancer

Alterations in the p16^INK4a/CDKN2A Tumor Suppressor Gene in Gastrinomas

Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (J.S., S.U.G., P.L.P., F.G., R.T.J.), and Laboratory of Pathology, National Cancer Institute (I.A.L.), National Institutes of Health, Bethesda, Maryland 20892

Address all correspondence and requests for reprints to: Dr. Robert T. Jensen, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9C-103, 10 Center Drive, MSC 1804, Bethesda, Maryland 20892-1804. E-mail: robertj{at}bdg10.niddk.nih.gov

The p16^INK4a/CDKN2A gene (p16^INK4a) is frequently altered by homozygous deletion, mutation, or methylation in many nonendocrine tumors, and these alterations may be predictive of recurrence, tumor growth, or aggressiveness. Whether this is true of neuroendocrine tumors such as gastrinomas is unclear. To address this question we analyzed the gastrinomas from 44 patients for p16^INK4a gene mutations and correlated the results to the tumor’s biological behavior, growth pattern, and aggressiveness. No gastrinomas had mutations of exon 1 or exon 2 of the p16^INK4a gene, although polymorphisms were found in 54%. No homozygous deletions were found. In 52% of the gastrinomas, hypermethylation of a 5'-CpG island of the p16^INK4a gene promoter was found. To assess the growth behavior of the gastrinomas, all patients were assessed yearly with at least three conventional imaging studies (computed tomography scan, magnetic resonance imaging, and ultrasound), and since 1994 have been assessed with radionuclide scanning using [¹¹¹In-diethylenetriamine pentaacetic acid,DPhe¹]octreotide. The mean follow-up was 5.1 ± 0.4 yr (range, 1.2–11.7). The presence or absence of methylation of the p16^INK4a gene did not correlate with clinical characteristics of the gastrinoma, biological behavior (gastrin release and basal or maximal acid output), the presence or absence of known prognostic factors (tumor size, gastrinoma location, lymph node metastases, liver metastases, and curability), or growth pattern of the gastrinoma postresection. These results indicate that methylation of the p16^INK4a gene is the most common gene alteration described to date in gastrinomas. Furthermore, because it is independent of disease stage it is probably an early event in the pathogenesis and because it is independent of the primary gastrinoma location, which is now thought to have different origins, methylation of the p16^INK4a gene is probably a central process in the molecular pathogenesis of these tumors.

This article has been cited by other articles:

				Y. Nagano, D. H. Kim, L. Zhang, J. A White, J. C Yao, S. R Hamilton, and A. Rashid Allelic alterations in pancreatic endocrine tumors identified by genome-wide single nucleotide polymorphism analysis Endocr. Relat. Cancer, June 1, 2007; 14(2): 483 - 492. [Abstract] [Full Text] [PDF]

				M. Furukawa, M. Raffeld, C. Mateo, A. Sakamoto, T. W. Moody, T. Ito, D. J. Venzon, J. Serrano, and R. T. Jensen Increased Expression of Insulin-Like Growth Factor I and/or Its Receptor in Gastrinomas Is Associated with Low Curability, Increased Growth, and Development of Metastases Clin. Cancer Res., May 1, 2005; 11(9): 3233 - 3242. [Abstract] [Full Text] [PDF]

				D. Furlan, R. Cerutti, S. Uccella, S. La Rosa, E. Rigoli, A. Genasetti, and C. Capella Different Molecular Profiles Characterize Well-Differentiated Endocrine Tumors and Poorly Differentiated Endocrine Carcinomas of the Gastroenteropancreatic Tract Clin. Cancer Res., February 1, 2004; 10(3): 947 - 957. [Abstract] [Full Text] [PDF]

				R. Schneider-Stock, C. Boltze, J. Lasota, M. Miettinen, B. Peters, M. Pross, A. Roessner, and T. Gunther High Prognostic Value of p16INK4 Alterations in Gastrointestinal Stromal Tumors J. Clin. Oncol., May 1, 2003; 21(9): 1688 - 1697. [Abstract] [Full Text] [PDF]

				A. Wild, A. Ramaswamy, P. Langer, I. Celik, V. Fendrich, B. Chaloupka, B. Simon, and D. K. Bartsch Frequent Methylation-Associated Silencing of the Tissue Inhibitor of Metalloproteinase-3 Gene in Pancreatic Endocrine Tumors J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1367 - 1373. [Abstract] [Full Text] [PDF]

				Y.-J. Chen, A. Vortmeyer, Z. Zhuang, S. Huang, and R. T. Jensen Loss of Heterozygosity of Chromosome 1q in Gastrinomas: Occurrence and Prognostic Significance Cancer Res., February 15, 2003; 63(4): 817 - 823. [Abstract] [Full Text] [PDF]

				S. U. Goebel, M. Iwamoto, M. Raffeld, F. Gibril, W. Hou, J. Serrano, and R. T. Jensen HER-2/neu Expression and Gene Amplification in Gastrinomas: Correlations with Tumor Biology, Growth, and Aggressiveness Cancer Res., July 1, 2002; 62(13): 3702 - 3710. [Abstract] [Full Text] [PDF]

				P. L. Peghini, M. Iwamoto, M. Raffeld, Y.-J. Chen, S. U. Goebel, J. Serrano, and R. T. Jensen Overexpression of Epidermal Growth Factor and Hepatocyte Growth Factor Receptors in a Proportion of Gastrinomas Correlates with Aggressive Growth and Lower Curability Clin. Cancer Res., July 1, 2002; 8(7): 2273 - 2285. [Abstract] [Full Text] [PDF]